CCCC - C4 Therapeutics Inc
IEX Last Trade
6.32
-0.110 -1.741%
Share volume: 784,021
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$6.43
-0.11
-1.71%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-03 | 2023-02-23 | 2023-05-04 | 2023-08-08 | 2023-11-01 | 2024-02-22 | 2024-05-08 | 2024-08-01 | |
| Assets | |||||||||
| Total Assets | 461.439 M | 430.840 M | 396.036 M | 375.008 M | 333.013 M | 376.451 M | 398.371 M | 381.093 M | |
| Current Assets | 325.456 M | 287.557 M | 278.452 M | 274.387 M | 223.686 M | 271.189 M | 279.592 M | 276.044 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 10.315 M | 9.931 M | 7.599 M | 6.074 M | 6.617 M | 5.709 M | 7.801 M | 10.779 M | |
| Short Term Investments | 10.315 M | 9.931 M | 7.599 M | 6.074 M | 6.617 M | 5.709 M | 7.801 M | 10.779 M | |
| Total Receivables | 1.488 M | 1.473 M | 528.000 K | 1.028 M | 500.000 K | 11.799 M | 13.599 M | 1.167 M | |
| Current Cash | 313.653 M | 276.153 M | 270.325 M | 267.285 M | 216.569 M | 253.681 M | 258.192 M | 264.098 M | |
| Total Non-current Assets | 135.983 M | 143.283 M | 117.584 M | 100.621 M | 109.327 M | 105.262 M | 118.779 M | 105.049 M | |
| Property Plant Equipment | 7.415 M | 7.400 M | 7.640 M | 7.572 M | 7.290 M | 7.132 M | 6.756 M | 6.571 M | |
| Other Assets | 72.931 M | 71.642 M | 71.959 M | 70.355 M | 68.726 M | 66.679 M | 67.605 M | 63.398 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 461.439 M | 430.840 M | 396.036 M | 375.008 M | 333.013 M | 376.451 M | 398.371 M | 381.093 M | |
| Total liabilities | 143.260 M | 141.606 M | 133.566 M | 141.301 M | 116.989 M | 130.337 M | 140.089 M | 134.035 M | |
| Total current liabilities | 45.267 M | 44.546 M | 39.380 M | 48.238 M | 30.271 M | 42.766 M | 55.018 M | 54.201 M | |
| Accounts Payable | 2.370 M | 1.172 M | 1.034 M | 2.247 M | 1.276 M | 1.446 M | 1.630 M | 913.000 K | |
| Other liabilities | 16.765 M | 16.895 M | 15.845 M | 24.647 M | 19.623 M | 21.814 M | 20.706 M | 16.910 M | |
| Current long term debt | 6.827 M | 6.987 M | 7.114 M | 15.291 M | 5.087 M | 5.219 M | 5.355 M | 5.493 M | |
| Long term debt | 81.228 M | 80.165 M | 78.341 M | 68.416 M | 67.095 M | 65.757 M | 64.365 M | 62.924 M | |
| Other liabilities | 16.765 M | 16.895 M | 15.845 M | 24.647 M | 19.623 M | 21.814 M | 20.706 M | 16.910 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 318.179 M | 289.234 M | 262.470 M | 233.707 M | 216.024 M | 246.114 M | 258.282 M | 247.058 M | |
| Common stock | 48.922 M | 48.966 M | 49.032 M | 49.064 M | 49.212 M | 51.254 M | 68.432 M | 68.810 M | |
| Retained earnings | -358.705 M | -395.890 M | -430.670 M | -466.592 M | -493.629 M | -528.383 M | -556.744 M | -574.460 M |